16 June 2017
BPC-M-20-2017

Minutes of the 20th meeting of the Biocidal Products Committee (BPC)

27 April 2017

Part I - Summary Record of the Proceedings

1. Welcome and apologies

The Chairman of the Biocidal Products Committee (BPC) welcomed the participants to the 20th BPC meeting and informed the meeting that no changes occurred recently in the BPC membership.

The Chairman introduced then Jukka Malm, ECHA's Deputy Executive Director, who gave the welcome address for this twentieth meeting of the Committee.

The Chairman informed the BPC members of the participation of 23 members, including one alternate.

Three advisers, two invited experts and one representative from accredited stakeholder organisations (ASOs) were present at the meeting. One representative from the European Commission also attended the meeting. Apologies were received from three members and one ASO.

Applicants were present for their specific substances and the details are provided in the summary record of the discussion for the substances and in Part III of the minutes.

2. Agreement of the agenda

The Chairman introduced the final draft agenda (BPC-A-20-2017_rev2) and invited then any additional items. No items were added.

The agenda was then adopted. The final version of the agenda will be uploaded to the BPC CIRCABC IG as part of the meeting minutes.

The Chairman informed the meeting participants that the meeting would be recorded for the purpose of the minutes and that the recording would be destroyed after the agreement of the minutes.

The list of meeting documents and the final version of the agenda are included in Part IV of the minutes.

3. Declarations of potential conflicts of interest to the agenda

The Chairman invited BPC members, alternates and advisers to declare any potential conflict of interest in relation to the agreed agenda. None was declared.

4. Agreement of the draft minutes and review of actions arising from BPC-19

The revised draft minutes from BPC-19 (BPC-M-19-2017), incorporating the comments received from members, were agreed. With regard to the actions following BPC-19, the Chairman noted that most of them have been carried out. BPC members were reminded that the written procedure for the adoption of the opinion for cypermethrin PT 18 has been launched and that their responses are awaited until 5 May 2017. With regard to

acetamiprid PT 18 the Chairman informed the meeting that (i) an e-consultation of the WG ENV will be launched on the additional data regarding the P status and (ii) following an e-consultation of the WG ENV organised after the last meeting on the derivation of the $PNEC_{soil}$ a value was agreed upon. To follow, the Chairman mentioned that an e-consultation of the BPC following several questions raised by the WG ENV will be launched soon. BPC members were then informed that one additional request pursuant to Article 75(1)(g) of the BPR was received from the Commission, related to the eligibility of corn cob for inclusion in Annex I, after an agreement on this at the CA meeting and it was proposed that ECHA would act as rapporteur for this request.

Actions:

- **SECR:** to upload the agreed minutes from BPC-19 to the BPC CIRCABC IG and to the ECHA website after the meeting.

5. Administrative issues

5.1 Housekeeping issues

The SECR highlighted the key aspects of the housekeeping rules including the safety and security rules.

5.2 Administrative updates and report from other ECHA bodies

The Chairman introduced document BPC-20-2017-01 covering the administrative updates and the report form the other ECHA Committees, provided to members for information purposes. The Chairman informed the meeting that two new accredited stakeholder organisations expressed an interest in the work of the BPC: COGECA (General Committee for Agricultural Cooperation in the European Union) and COPA (Committee of Professional Agricultural Organisations).

The BPC members agreed to the two organisations as BPC accredited stakeholder observers.

Actions:

- **SECR:** to update the list of ASOs and publish it on the ECHA website.

6. Work Programme for BPC

6.1 BPC Work Programme 2017-2018

6.2 Outlook for the BPC

The Chairman presented the revised Work Programme, mentioning that this version is a revised version of the previously disseminated one, following consultations with the MSCAs.

With regard to the outlook for the BPC, the Chairman stated that compared to the planning available at the last meeting, many dossiers had to be removed from the work programme, due to delays in the submission or failure at the accordance check step, thus causing a considerable decrease in the number of the opinions for the Review Programme to be adopted this year. The Chairman expressed the concerns of SECR about not meeting the objective of 50 opinions adopted in 2017 for approval of existing active substances and referred to the discussion at the last CA meeting on the progress of the Review Programme.

The Commission reiterated its concerns about this situation, where the number of planned dossiers being discussed in the BPC is decreasing from meeting to meeting. The objective of 50 opinions is not planned to be met this year. After the last CA meeting, the Commission did not receive any comment or proposal from Member States to improve this situation. A follow-up discussion is planned at the next CA meeting in May, The Commission invited Member States to reflect on the matter.

As communicated also at the last meeting, it was mentioned that the first BPC discussion on Union authorisation applications (for iodine for PT 3) is likely to take place at the last BPC meeting of 2017.

Actions:

- **Members**: to send information on any further changes to the Work Programme (WP) to the SECR **by 5 May 2017**.
- **SECR**: on the basis of the changes to update the work programme on the ECHA web site and in the BPC CIRCABC IG.

6.3 Overview of ongoing guidance development

SECR introduced the document presenting the status of ongoing guidance development and it was mentioned that an update on this status will be provided regularly to the BPC Working Groups. SECR proposed to present such an update also to the BPC; this would be relevant especially for those member states not participating in the working groups. It was noted that a considerable number of requests related to the development of guidance and other harmonising documents are received by the BPC Working Groups and that these requests will have to be prioritised as resources in both MS and ECHA do not allow to address all of them and the projects have to fit in the work programme of the WGs. SECR will prioritise after consulting the relevant fora (e.g. WGs and/or BPC and Coordination Group).

Actions:

- **SECR:** to consult the relevant fora on the most important topics and define the prioritisation.
- **SECR:** to regularly (e.g. twice a year) present the ongoing guidance development to the BPC and other relevant fora like the CA and CG meetings.

7. Applications for approval of active substances

7.1 Draft BPC opinion on L(+) lactic acid for PTs 2, 3 and 4

The Chairman noted that the applicant was not present during the meeting.

The rapporteur introduced the substance and the general issues related to the assessment report (AR) and the opinions were then discussed in detail (modifications are described in the open issues table).

The main discussion related to the unacceptable risks identified in PT3 in groundwater for direct release to soil (via manure application) and the fact that the substance is proposed for Annex I inclusion. The rapporteur mentioned that the exposure assessment for the application of manure to agricultural land results in groundwater concentrations above the limit of 0.1 µg/L due to a conservative estimation of the degradation in soil based on the results from a ready biodegradability test. Several members proposed to perform a qualitative assessment, taking into account literature data and expert judgement, which could substantiate the overestimation of the identified risk and subsequently reverse the conclusion on the existence of the risk.

The rapporteur stated that a degradation test in soil would not be the appropriate study to require but that it can be considered to provide another ready biodegradability study (to show that the so-called 10 day window criterion is passed). It was concluded that an additional degradation study in soil to refine the risk would not be required, but that a ready biodegradability test can be performed as an option if necessary at product authorisation.

On this point, a general discussion will need to be initiated on the assessment of low hazard substances due to resultant data waiving and the use of weight of evidence (including expert judgement) for such substances.

Another point discussed was the new proposal by the rapporteur included in the CLH dossier to classify L-(+)-Lactic acid as STOT SE 3 for respiratory irritation. Since this proposal for classification had not been included in the draft CAR and was not included for the active substance under PT1 it was agreed to remove the proposed classification for STOT SE 3. In the section proposing the eligibility of L-(+)-Lactic acid for Annex I inclusion a reference will be made to the ongoing CLH process.

Several other points were discussed in the AR and the opinions which were included in the open issues table.

The assessment report was agreed by the BPC. The BPC adopted by consensus the opinion for the approval of the active substance for PT 2 and PT 4 and by majority for PT 3. The member from Denmark will submit a minority opinion for PT 3 as they did not support the proposal that the active substance is eligible for Annex I considering that currently an unacceptable risk for groundwater is identified.

The Commission commented that, as for the other existing active substances that the BPC found eligible for Annex I inclusion after full evaluation, it does not intend to include lactic acid yet in Annex I, and only intend to propose an approval for now. A more general discussion on the management of Annex I is indeed needed at CA meeting level due to rising questions on this Annex.

Actions:

- **Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR **by 9 June 2017.**
- **Member:** to submit the minority position for lactic acid in PT 3 **by 5 May 2017.**
- **SECR:** to revise the draft opinions in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur.
- **SECR:** to forward the adopted opinions to COM **by 16 May 2017** and publish them on the ECHA website.

7.2 Draft BPC opinion on propan-1-ol for PTs 1, 2 and 4

The Chairman welcomed the applicant for this item. The rapporteur introduced the substance and the general issues related to the assessment report (AR) and the opinions were then discussed in detail (modifications are described in the open issues table).

The risk mitigation measures (RMM) and labelling triggered from the classification of propan-1-ol as Eye Damage 1 (H318) for the non-professional users were discussed for all product types. Since non-professional users are not expected to use personal protective equipment, during the risk characterisation of the active substance product integrated RMMs and labelling such as "avoid contact with eyes" had been taken into account. Similar product integrated RMMs and labelling might be required at product authorisation stage.

Propan-1-ol is used in PT 1 for hand disinfection of professionals, where an unacceptable risk was identified for products with 70 % propan-1-ol. Since PPE (i.e. gloves and RPE) are not applicable in this scenario a lower concentration of propan-1-ol in the product was taken into account, considering that according to efficacy evaluation, products with 60 % of active substance are still effective.

The BPC concluded that a safe use for human health and environment has been identified for non-professional and professional use of the ready-to-use biocidal product containing ≤60 % of propan-1-ol. Several other points were discussed in the AR and the opinions which are included in the open issues table.

The assessment report was agreed by the BPC. The BPC adopted by consensus the opinion for the approval of this active substance in all the PT combinations.

Actions:

- **Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR **by 9 June 2017**.
- **SECR:** to revise the draft opinions in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur.
- **SECR:** to forward the adopted opinions to COM **by 16 May 2017** and publish them on the ECHA website.

7.3 Use of human data

The use of historical human data for the evaluation of an active substance, in particular related to Annex IV of the BPR was discussed in a closed session. The Commission will consider the need to further discuss this point at a subsequent Competent Authorities (CA) meeting. As the evaluation for the active substance was submitted by the eCA before 1 September 2013, the interaction with Article 90(2) and the full application of the provisions of Annex IV to the BPR, which includes a provision on the use of human data, needs to be clarified.

Actions:

- **SECR:** to forward the issue to the Commission, in particular the application of Annex IV and the interaction with Article 90(2).

7.4 Revised Assessment Report following the submission of data after active substance approval for the renewal of warfarin PT 14

The member from IE introduced the relevant documents and the BPC members were invited to agree on the revised List of Endpoints (LoEP) and on the Assessment Report. Several comments were made during the commenting phase where the members agreed with the proposal on how to incorporate these by IE. On one minor comment from the member from the UK some further clarification was required which will dealt with after the meeting. .

Actions:

- **Member:** to submit the revised Assessment report including the List of Endpoints to **SECR**.
- **SECR**: to disseminate the revised Assessment Report on CIRCABC and on the ECHA website.

7.5 Assessment of ED properties in view of future ED criteria

The SECR informed the BPC on the on-going developments on the future ED criteria including the implementation of them in the active substance approval process and guidance development.

8. Union authorisation

8.1 Update on Union authorisation

An update on Union authorisation was given by the SECR to present: an overview of the current status of the applications submitted so far; an outline of the ongoing activities; and the planning for the discussions at the Working Group and BPC meetings of the applications expected to enter the peer-review phase in 2017.

Actions:

- **SECR**: to upload the presentation to S-CIRCABC.

8.2 Status of hydrogen peroxide in applications for peracetic acid alone or peracetic acid and hydrogen peroxide

The Chairman introduced the document AP 08.02 and presented the overview table listing the pre-submission applications for Union authorisation for products based on peracetic acid. In some of them, hydrogen peroxide was identified as a second active substance and the views of the BPC members were requested as to whether hydrogen peroxide should be considered as a second active substance in such applications.

Two members were in favour of considering hydrogen peroxide as a second active substance. One member pointed out that when peracetic acid is obtained in the form of an aqueous equilibrium solution containing peracetic acid, acetic acid, hydrogen peroxide and water, the efficacy of hydrogen peroxide is negligible. Moreover, the specification for the aqueous equilibrium solution was based on the starting materials acetic acid and hydrogen peroxide and no concentration limits were set for hydrogen peroxide. Those arguments supported that hydrogen peroxide is not a second active substance in the aqueous equilibrium solution.

The BPC agreed that hydrogen peroxide is not a second active substance in the case of a biocidal product based on the active substance peracetic acid.

10. Agreement of the action points and conclusions

Part II contains the main conclusions and action points which were agreed at the meeting.

Part II - Main conclusions and action points

Agreed at the 20th meeting of BPC

27 April 2017

Agenda point	
Conclusions / decisions / minority positions	**Action requested after the meeting (by whom/by when)**
Item 2 - Agreement of the agenda	
The final draft agenda was agreed without changes.	**SECR:** to upload the agreed final agenda to the BPC CIRCABC IG as part of the draft meeting minutes after the meeting.
Item 4 - Agreement of the minutes and review of actions from BPC-19	
The revised version of the minutes of BPC-19 was agreed as proposed subject to several editorial modifications.	**SECR:** to upload the agreed minutes to the BPC CIRCABC IG and to the ECHA website after the meeting.
Item 5.2 Administrative issues	
The BPC agreed to accept the two new organisations to be included in the list of the ECHA accredited stakeholder organisations (ASOs).	**SECR:** to update the list of ASOs and publish it on the ECHA website.
Item 6 - Work programme for BPC	
6.1 Revised Work Programme 2017-2018 and Outlook for BPC	
	Members: to send information on any further changes to the Work Programme (WP) to the SECR by **5 May 2017.** **SECR:** on the basis of the changes to update the WP on the ECHA web site and in the BPC CIRCABC IG.
6.3 Overview of ongoing guidance development	
	SECR: to present the ongoing guidance development for the various stakeholders (BPC and WGs, CA, CG). To develop a proposal for rules and procedures for prioritisation of guidance development.
Item 7 - Applications for approval of active substances	
7.1 Draft BPC opinion on L(+) lactic acid for PTs 2, 3 and 4	
The BPC adopted by consensus the opinions for the approval of lactic acid for PT 2 and 4 and by	**Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and

majority the approval of lactic acid for PT 3.	submit to the SECR by **9 June 2017.** **Member:** to submit the minority position for lactic acid in PT 3 by **5 May 2017.** **SECR:** to revise the draft opinions in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur. **SECR:** to forward the adopted opinions to COM by **16 May 2017** and publish them on the ECHA website.
7.2 Draft BPC opinion on propan-1-ol for PTs 1, 2 and 4	
The BPC adopted by consensus the opinions for the approval of the active substance/PT combinations.	**Rapporteur:** to revise the assessment report in accordance with the discussions in the BPC and submit to the SECR **by 9 June 2017.** **SECR:** to revise the draft opinions in accordance with the discussions in the BPC and carry out an editorial check in consultation with the rapporteur. **SECR:** to forward the adopted opinions to COM by **16 May 2017** and publish them on the ECHA website.
7.3 Use of human data	
The issue will be discussed at the CA meeting, in particular the application of Annex IV and the interaction with Article 90(2).	
7.4 Revised AR following the submission of data after active substance approval for the renewal of warfarin PT 14	
The BPC agreed to the amending of the AR.	**Rapporteur:** to revise the AR. **SECR:** to disseminate the revised AR on CIRCABC and on the ECHA website.
7.5 Assessment of ED properties in view of future ED criteria	
The SECR updated the BPC on the developments related to the ED criteria and its implementation.	**SECR:** to open a Newsgroup on S-CIRCABC. **Members:** to submit comments on the presentation by **24 May 2017.**
7.6 Revised template for the BPC opinion and Assessment Report	
	SECR: to open a Newsgroup on S-CIRCABC. **Members:** to submit comments on the revised templates by **24 May 2017**.
Item 8 – Union authorisation	
8.1 Update on Union authorisation	
The SECR updated the BPC on the status of Union Authorisations.	**SECR:** to upload the presentation to S-CIRCABC.

8.2 Status of hydrogen peroxide in applications for peracetic acid alone or peracetic acid and hydrogen peroxide	
The BPC agreed that hydrogen peroxide is not a second active in the on-going pre-submission cases for peracetic acid.	

Part III - List of Attendees

Members	European Commission
BORGES Teresa (PT)	CHATELIN Ludovic (DG SANTE)
BROWN Finbar (IE)	
CABALLO DIÉGUEZ Covadonga (ES)	**Advisers**
ČEBAŠEK Petra (SI)	PALOMÄKI Jaana (FI)
CHEZEAU Aurélie (FR)	RITZ Vera (DE)
COSTIGAN Michael (UK)	WEINHEIMER Viola (DE)
DRAGOIU Mihaela-Simona (RO)	
GORDON Suzanne (NO)	**Accredited Stakeholder Organisations**
HADJIGEORGIOU Andreas (CY)	MONTMOREAU Bertrand (CEPA)
HAHLBECK Edda (SE)	
JÄGER Stefanie (DE)	**ECHA Staff**
JOHN Nina (AT)	AIRAKSINEN Antero
KOIVISTO Sanna (FI)	ESTEVAN MARTINEZ Carmen
KOMEN Corine (NL)	JANOSSY Judit
LARSEN Jørgen (DK)	KENIGSWALD Hugues
MERISTE Anu (EE)	NEGULICI Ligia
MIKOLASKOVA Denisa (SK)	PECORINI Chiara
RUSCONI Manuel (CH)	VAN DE PLASSCHE Erik
VACEK Tomas (CZ)	
VAN BERLO Boris (BE)	
ZIGRAND Jeff (LU)	
ZOUNOS Athanasios (EL)	
Alternate members	
SZENTGYÖRGYI Tímea (HU)	
Invited experts	
HADAM Anna (PL)	
JANTONE Anta (LV)	

Applicants	Apologies
GERDES Herta (Task force propan-1-ol) for propan-1-ol PT 1, 2, 4	GIORDMAINA Wayne (MT)
MOSTERT Volker (Saltigo GmbH) for agenda item 7.3	MIHAI Camelia (CEFIC)
	RUBBIANI Maristella (IT)
Experts accompanying applicants	VRHOVAC FILIPOVIC Ivana (HR)
LICHT Oliver, accompanying GERDES Herta, for propan-1-ol PT 1, 2, 4	

Part IV - List of Annexes

Annex I List of documents submitted to the members of the Biocidal Products Committee

Annex II Final agenda of BPC-20

Annex I

Documents submitted to the members of the Biocidal Products Committee for the BPC-20 meeting

Meeting documents			
Agenda Point	**Number**	**Title**	
2	BPC-A-20-2017	Draft agenda	
4	BPC-M-19-2017	Draft minutes from BPC-19	
5.2	BPC-20-2017-01	Administrative issues and report from the other Committees	
6.1	BPC-20-2017-02	BPC updated Work Programme 2017-2018	
6.2	BPC-20-2017-03	Outlook for the BPC	
6.3	BPC-20-2017-16	Overview of ongoing guidance development	
7.3	BPC-20-2017-10 BPC-20-2017-18	Use of human data	
7.4	BPC-20-2017-12	Revised AR following the submission of data after active substance approval for the renewal of warfarin PT 14	
7.5	BPC-20-2017-13	Assessment of ED properties in view of future ED criteria	
7.6	BPC-20-2017-14 BPC-20-2017-15	Revised template for the BPC opinion and the Assessment Report	
8.1	BPC-20-2017-11	Update on Union authorisation	
8.2	BPC-20-2017-17	Status of hydrogen peroxide in applications for peracetic acid alone or peracetic acid and hydrogen peroxide	
Substance documents			
Agenda Point	**Number**	**Substance-PT**	**Title**
7.1	BPC-20-2017-04A	L(+) lactic acid PT 2	Draft BPC opinion
	BPC-20-2017-04B		Assessment report
	BPC-20-2017-04C		Open issues
	BPC-20-2017-05A	L(+) lactic acid PT 3	Draft BPC opinion
	BPC-20-2017-04B		Assessment report
	BPC-20-2017-04C		Open issues

	BPC-20-2017-06A	L(+) lactic acid PT 4	Draft BPC opinion
	BPC-20-2017-04B		Assessment report
	BPC-20-2017-04C		Open issues
7.2	BPC-20-2017-07A	Propan-1-ol PT 1	Draft BPC opinion
	BPC-20-2017-07B		Assessment report
	BPC-20-2017-07C		Open issues
	BPC-20-2017-08A	Propan-1-ol PT 2	Draft BPC opinion
	BPC-20-2017-07B		Assessment report
	BPC-20-2017-07C		Open issues
	BPC-20-2017-09A	Propan-1-ol PT 4	Draft BPC opinion
	BPC-20-2017-07B		Assessment report
	BPC-20-2017-07C		Open issues

21 April 2017
BPC-A-20-2017_rev2

Final draft agenda
20th meeting of the Biocidal Products Committee (BPC)
27 April 2017
ECHA Conference Centre, Annankatu 18, Helsinki
Starts at 09:30, ends at 16:00

1. – Welcome and apologies

- **Welcome address by ECHA's Deputy Executive Director, Mr Jukka Malm**

2. – Agreement of the agenda

BPC-A-20-2017_rev2
For agreement

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-19

BPC-M-19-2017
For agreement

5. – Administrative issues

5.1. Housekeeping issues

For information

5.2. Other administrative issues and report from other Committees

BPC-20-2017-01
For information

6. – Work programme for BPC

6.1. Revised BPC Work Programme 2017-2018

BPC-20-2017-02
For information

6.2. Outlook for BPC

BPC-20-2017-03
For information

6.3. Overview ongoing guidance development

BPC-20-2017-16
For information

7. – Applications for approval of active substances*

7.1. Draft BPC opinion L(+) lactic acid for PTs 2, 3 and 4

Previous discussion(s): WG-V-2016

PT 2: BPC-20-2017-04A, B and C
PT 3: BPC-20-2017-05A and BPC-20-2017-04B, C
PT 4: BPC-20-2017-06A and BPC-20-2017-04B, C

For adoption

7.2. Draft BPC opinion on propan-1-ol for PTs 1, 2 and 4

Previous discussion(s): WG-I-2017

PT 1: BPC-20-2017-07A, B and C
PT 2: BPC-20-2017-08A and BPC-20-2017-07B, C
PT 4: BPC-20-2017-09A and BPC-20-2017-07B, C

For adoption

7.3. Use of human data

BPC-20-2017-10 and 18
For agreement

7.4. Revised Assessment Report following the submission of data after active substance approval for the renewal of warfarin PT 14

BPC-20-2017-12
For agreement

7.5. Assessment of ED properties in view of future ED criteria

BPC-20-2017-13
For information

* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

7.6. Revised template for the BPC opinion and the Assessment Report

BPC-20-2017-14 and 15

For agreement

Item 8 – Union authorisation

8.1. Update on Union authorisation

BPC-20-2017-11

For information

8.2. Status of hydrogen peroxide in applications for peracetic acid alone or peracetic acid and hydrogen peroxide

BPC-20-2017-17

For discussion

Item 9 – Any other business

Item 10 – Agreement of the action points and conclusions

For agreement

Provisional timeline for the

20th meeting of the Biocidal Products Committee (BPC)

ECHA Conference Centre, Annankatu 18, Helsinki
27 April 2017: starts at 09:30; ends at 16:00

Please note that the timings indicated below are provisional and subject to possible change. They are distributed to participants on a preliminary basis.

Thursday 27 April: morning session

Items 1-5	Opening items and administrative issues
Item 6	Work programme of the BPC 2017-18
Item 7.1	Draft BPC opinion on L(+) lactic acid for PTs 2, 3 and 4
Item 7.2	Draft BPC opinion on propan-1-ol for PTs 1, 2 and 4

Thursday 27: afternoon session

Item 7.2	(cont'd) Draft BPC opinion on propan-1-ol for PTs 1, 2 and 4
Item 7.3	Use of human data
Item 7.4	Revised Assessment Report following the submission of data after active substance approval for warfarin PT 14
Item 7.5	Assessment of ED properties in view of future ED criteria
Item 7.6	Template BPC opinion and Assessment Report
Item 8	Union authorisation
Item 9	AOB
Item 10	Agreement of the action points and conclusions

End of meeting

o0o